[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-361328-105":59,"doc-detail-361328-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","enzymatic-activity-independent-nans-stabilizes-lats2-to-drive-growth-and-therapeutic-resistance-in-hrher2-breast-cancer-article","Enzymatic activity-independent NANS stabilizes LATS2 to drive growth and therapeutic resistance in HR+/HER2-breast cancer - Article","","Enzymatic activity-independent NANS is reported as a key driver in hormone receptor-positive, HER2-negative (HR+/HER2−) breast cancer. NANS is upregulated in patient samples and inversely correlates with prognosis. Functionally, NANS promotes tumor growth and enables resistance to tamoxifen and CDK4/6 inhibitors without relying on canonical enzymatic activity. Mechanistically, NANS recruits USP7 to deubiquitinate and stabilize LATS2, activating the Hippo pathway and increasing estrogen receptor α and CDK4 expression. Reintroducing LATS2 partially restores growth and drug sensitivity in models, supporting the NANS–USP7/LATS2 axis as a therapeutic target.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/enzymatic-activity-independent-nans-stabilizes-lats2-to-drive-growth-and-therapeutic-resistance-in-hrher2-breast-cancer-article/361328/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/enzymatic-activity-independent-nans-stabilizes-lats2-to-drive-growth-and-therapeutic-resistance-in-hrher2-breast-cancer-article/361328.png","ImageObject",300,407,{"name":92,"@type":93},"mieayamfan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-20","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does NANS play in HR+/HER2− breast cancer progression?","Question",{"text":112,"@type":113},"NANS is significantly upregulated and functionally promotes tumor growth in HR+/HER2− breast cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does NANS confer resistance to endocrine therapy and CDK4/6 inhibitors?",{"text":117,"@type":113},"NANS drives resistance to tamoxifen and CDK4/6 inhibitors independently of its canonical enzymatic activity.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the mechanism connecting NANS, USP7, and LATS2?",{"text":121,"@type":113},"NANS recruits USP7 to deubiquitinate and stabilize LATS2, triggering canonical Hippo pathway activation and upregulating estrogen receptor α and CDK4.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},361328,1790205590,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},962090893677,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Article [https://doi.org/10.1038/s41467-026-75386-x](https://doi.org/10.1038/s41467-026-75386-x)  \nEnzymatic activity-independent NANS stabilizes LATS2 to drive growth and therapeutic resistance in HR+/HER2-breast cancer  \nReceived: 15 June 2025  \n\n| Accepted: 29 June 2026 |\n| --- |\n| |\n| Check for updates |\n\nJia-Yang Cai1,2,5, Min-Ying Huang3,4,5, Shao-Ying Yang2,3, Fang-Lin Zhang 3  \n,  \nYin-Ling Zhang3, Lisa Andriani1, Qian Zhao1,2,3, A-Yong Cao1,2 , Da-Qiang Li 1,2,3  & Zhi-Ming Shao 1,2,3   \nHormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+ /HER2-) breast cancer is the most common subtype in females, frequently challenged by resistance to endocrine therapy and CDK4/6 inhibitors. Here we show that N-acetylneuraminate synthase (NANS) is signiﬁcantly upregulated in female HR+ /HER2-breast cancer patients, inversely correlating with patient prognosis. Functionally, NANS promotes tumor growth and confers resistance to tamoxifen and CDK4/6 inhibitors independently of its canonical enzymatic activity. Mechanistically, NANS recruits ubiquitin-speciﬁc protease 7 (USP7) to deubiquitinate and stabilize large tumor suppressor kinase 2 (LATS2), leading to canonical Hippo pathway activation and upregulation of estrogen receptor α and CDK4. Reintroducing LATS2 into NANS-depleted cells partially rescues the impaired growthpromoting and drug-resistant phenotypes in vitro and in vivo. Furthermore, the clinical relevance of the NANS-USP7/LATS2 axis is conﬁrmed in patientderived female HR+ /HER2-breast cancer samples. Together, our ﬁndings unveil an enzymatic activity-independent role for NANS in driving therapy resistance, nominating it as a promising therapeutic target.  \nBreast cancer (BC) is a highly heterogeneous disease and includes distinct molecular subtypes that are intimately linked to different therapeutic strategies and clinical outcomes1. BC is generally classiﬁed into three primary molecular subtypes on the basis of the expression status of estrogen and progesterone receptors (collectively referred to as hormone receptors, HR) and human epidermal growth factor receptor 2 (HER2). These subtypes include HR-positive and HER2-negative (HR+ /HER2-), HER2-positive (HER2+ ), and triple-negative breast cancer (TNBC)2,3. Among them, HR+ /HER2- is the most  \ncommon subtype, accounting for approximately two-thirds of all primary BC cases4.  \nClinically, endocrine therapy (ET), such as the selective estrogen receptor (ER) modulator tamoxifen, the ER degrader fulvestrant, and aromatase inhibitors that block estrogen production, is the mainstay of treatment for patients with HR+ /HER2- BC5. However, ~ 20% of patients with early-stage disease and nearly all patients with advanced/ metastatic disease eventually develop endocrine resistance5. Accumulating evidence has shown that abnormal activation of cyclin-  \n1Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China. 2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. 3Cancer Institute, Shanghai Medical College, Fudan University, Shanghai, China. 4Institutes of Biomedical Sciences, Fudan University, Shanghai, China. 5These authors contributed equally: Jia-Yang Cai, Min-Ying Huang.  \ne-mail: [caoayong@fudan.edu.cn](caoayong@fudan.edu.cn); [daqiangli1974@fudan.edu.cn](daqiangli1974@fudan.edu.cn); [zhimingshao@fudan.edu.cn](zhimingshao@fudan.edu.cn)  \ndependent kinases 4 and 6 (CDK4/6) and their binding partner cyclin Dis among the major mechanisms of endocrine resistance6–8. Consequently, the combination of ET with a selective CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) has become the standard ﬁrstline treatment for advanced/metastatic HR+ /HER2- BC4,9,10. Although CDK4/6 inhibitors are effective in these clinical settings, nearly all patients eventually develop resistance and succumb to the disease9. However, the molecular mechanisms drivin","cbCaipWd3rGVMBmd","https://ap.wps.com/l/cbCaipWd3rGVMBmd","pdf",4147378,"English","# Introduction\n# NANS in HR+/HER2- breast cancer\n# Hippo pathway and LATS2\n# Endocrine therapy and CDK4/6 inhibitor resistance","[{\"question\":\"What role does NANS play in HR+/HER2− breast cancer progression?\",\"answer\":\"NANS is significantly upregulated and functionally promotes tumor growth in HR+/HER2− breast cancer.\"},{\"question\":\"How does NANS confer resistance to endocrine therapy and CDK4/6 inhibitors?\",\"answer\":\"NANS drives resistance to tamoxifen and CDK4/6 inhibitors independently of its canonical enzymatic activity.\"},{\"question\":\"What is the mechanism connecting NANS, USP7, and LATS2?\",\"answer\":\"NANS recruits USP7 to deubiquitinate and stabilize LATS2, triggering canonical Hippo pathway activation and upregulating estrogen receptor α and CDK4.\"}]","Enzymatic activity-independent NANS stabilizes LATS2 to drive growth and therapeutic resistance in HR+/HER2-breast cancer - Article | PDF",1790143951,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e8a8f6a125d00a638c55d887d4cd3960.webp",983,1305,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b17c65a8b219990de236d3196e1a9642.webp",982,1304,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/47a81a366c9a36dbc2a831244b199f23.webp",981,1303,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/52300c92fea3b1219ab74bdd1013520d.webp",980,1301]